Erik Tillman
Company: Akero Therapeutics
Job title: Associate Director - Translational Biology & Pharmacology
Seminars:
Chair’s Closing Remarks 2:30 pm
day: Seminar B PM tracks
Improvements in Non-Invasive Biomarkers & Their Correlation to Histology: Significance of Eliminating the Disease Driver in Achieving a Sustained Benefit 9:30 am
Discuss the importance of consistency of effect across the different markers of NASH pathophysiology including liver fat, liver injury and fibrosis Discuss the normalization of non-invasive parameters with EFX and correlation with histologic improvement Significance of eliminating underlying disease drivers to achieve a sustained responseRead more
day: Seminar B- AM tracks
Reimagining Non-Invasive Biomarkers for Improved Clinical Outcome to Move the Needle on Validation
Seminar Moderators: 9:24 am
Seminar Moderators:
day: Seminar B- AM tracks